Identification
NameCastanospermine
Accession NumberDB01816  (EXPT01055)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
Synonyms
(1S-(1α,6β,7α,8β,8αβ))-octahydro-1,6,7,8-indolizinetetrol
(1S,6S,7R,8R,8aR)-1,6,7,8-tetrahydroxyindolizidine
1,6,7,8-tetrahydroxyoctahydroindolizine
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIQ0I3184XM7
CAS number79831-76-8
WeightAverage: 189.209
Monoisotopic: 189.100107973
Chemical FormulaC8H15NO4
InChI KeyJDVVGAQPNNXQDW-TVNFTVLESA-N
InChI
InChI=1S/C8H15NO4/c10-4-1-2-9-3-5(11)7(12)8(13)6(4)9/h4-8,10-13H,1-3H2/t4-,5-,6+,7+,8+/m0/s1
IUPAC Name
(1S,6S,7R,8R,8aR)-octahydroindolizine-1,6,7,8-tetrol
SMILES
[H][C@]1(O)CCN2C[C@]([H])(O)[C@@]([H])(O)[C@]([H])(O)[C@@]12[H]
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucan 1,3-beta-glucosidaseProteinunknownNot AvailableYeastP29717 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 5-androstenedione.Experimental, Illicit
AbciximabCastanospermine may increase the anticoagulant activities of Abciximab.Approved
AcebutololCastanospermine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aceclofenac.Approved
AcenocoumarolCastanospermine may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Castanospermine.Approved, Vet Approved
AclarubicinCastanospermine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Castanospermine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alendronic acid.Approved
AliskirenCastanospermine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololCastanospermine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Castanospermine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Amcinonide.Approved
AmikacinCastanospermine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideCastanospermine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinCastanospermine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodCastanospermine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with HMPL-004.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Castanospermine.Approved
Antithrombin III humanCastanospermine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCastanospermine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Castanospermine is combined with Acetovanillone.Investigational
ApramycinCastanospermine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Castanospermine is combined with Apremilast.Approved, Investigational
ArbekacinCastanospermine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinCastanospermine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanCastanospermine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololCastanospermine may decrease the antihypertensive activities of Arotinolol.Approved
Arsenic trioxideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololCastanospermine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Castanospermine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Castanospermine.Approved
BalsalazideCastanospermine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Castanospermine.Investigational
BecaplerminCastanospermine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCastanospermine may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Castanospermine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Castanospermine.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Castanospermine.Investigational
BetamethasoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololCastanospermine may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Betulinic Acid.Investigational
BevantololCastanospermine may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Castanospermine.Approved, Investigational
BisoprololCastanospermine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCastanospermine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCastanospermine may decrease the antihypertensive activities of Bopindolol.Approved
BrexpiprazoleThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Brexpiprazole.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Castanospermine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bucillamine.Investigational
BucindololCastanospermine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Budesonide.Approved
BufuralolCastanospermine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideCastanospermine may decrease the diuretic activities of Bumetanide.Approved
BupranololCastanospermine may decrease the antihypertensive activities of Bupranolol.Approved
BuserelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Buserelin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Castanospermine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Castanospermine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Castanospermine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Castanospermine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Castanospermine.Approved, Vet Approved, Withdrawn
CarteololCastanospermine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCastanospermine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Celecoxib.Approved, Investigational
CeliprololCastanospermine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ceritinib.Approved
CertoparinCastanospermine may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Castanospermine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Castanospermine.Approved, Vet Approved
ChlorpropamideCastanospermine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Castanospermine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Castanospermine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Castanospermine.Approved
CinoxacinCastanospermine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinCastanospermine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidCastanospermine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clonixin.Approved
ClozapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Clozapine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CorticotropinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Castanospermine is combined with Curcumin.Investigational
CyclosporineCastanospermine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateCastanospermine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dabrafenib.Approved
DalteparinCastanospermine may increase the anticoagulant activities of Dalteparin.Approved
DanazolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Danazol.Approved
DarexabanCastanospermine may increase the anticoagulant activities of Ym150.Investigational
DarunavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Darunavir.Approved
DaunorubicinCastanospermine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Castanospermine is combined with Deferasirox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Castanospermine.Approved
DesirudinCastanospermine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.Approved
DesogestrelThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Desogestrel.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoximetasone.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Castanospermine.Approved
DextranCastanospermine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Castanospermine may increase the anticoagulant activities of Dextran 40.Approved
DiazoxideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Diazoxide.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Castanospermine.Approved, Vet Approved
DicoumarolCastanospermine may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dienogest.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Castanospermine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Castanospermine.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Castanospermine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Castanospermine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Castanospermine.Approved
DisopyramideCastanospermine may increase the hypoglycemic activities of Disopyramide.Approved
DoxorubicinCastanospermine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneCastanospermine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Castanospermine is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ebselen.Investigational
Edetic AcidCastanospermine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCastanospermine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Castanospermine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Castanospermine.Approved
EnoxacinCastanospermine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinCastanospermine may increase the anticoagulant activities of Enoxaparin.Approved
EpinephrineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of adverse effects can be increased when Castanospermine is combined with Epirizole.Approved
EpirubicinCastanospermine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneCastanospermine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Castanospermine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Castanospermine.Approved
EquileninThe risk or severity of adverse effects can be increased when Castanospermine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Equilin.Approved
EsmololCastanospermine may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Estrone.Approved
Estrone sulfateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidCastanospermine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.Approved, Investigational
Ethinyl EstradiolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateCastanospermine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethynodiol diacetate.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etofenamate.Approved
EtonogestrelThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etoricoxib.Approved, Investigational
EverolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Everolimus.Approved
FenbufenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Castanospermine.Approved
FingolimodCastanospermine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinCastanospermine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Castanospermine.Approved, Withdrawn
FludrocortisoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fludrocortisone.Approved
FluindioneCastanospermine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineCastanospermine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluprednidene.Approved, Withdrawn
FlurandrenolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Castanospermine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Castanospermine.Approved, Nutraceutical, Vet Approved
FondaparinuxCastanospermine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumCastanospermine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Castanospermine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fosamprenavir.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Castanospermine.Approved
FramycetinCastanospermine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideCastanospermine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Castanospermine is combined with G17DT.Investigational
GabexateCastanospermine may increase the anticoagulant activities of Gabexate.Investigational
GatifloxacinCastanospermine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Castanospermine.Approved, Withdrawn
GemifloxacinCastanospermine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCastanospermine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinCastanospermine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACastanospermine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GliclazideCastanospermine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCastanospermine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCastanospermine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideCastanospermine may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Goserelin.Approved
GrepafloxacinCastanospermine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Castanospermine is combined with HE3286.Investigational
HeparinCastanospermine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Higenamine.Investigational
HistrelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Histrelin.Approved
HydralazineCastanospermine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Castanospermine.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Castanospermine.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IbandronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Castanospermine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Castanospermine is combined with Icatibant.Approved
IdarubicinCastanospermine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IloperidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Iloperidone.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Castanospermine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Castanospermine.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Castanospermine.Approved
IndenololCastanospermine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Castanospermine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Castanospermine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Castanospermine is combined with INGN 225.Investigational
Insulin AspartCastanospermine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCastanospermine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCastanospermine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCastanospermine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCastanospermine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCastanospermine may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Castanospermine.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Isoxicam.Withdrawn
KanamycinCastanospermine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Castanospermine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Castanospermine.Approved
LabetalolCastanospermine may decrease the antihypertensive activities of Labetalol.Approved
LandiololCastanospermine may decrease the antihypertensive activities of Aop200704.Investigational
LanreotideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lanreotide.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Castanospermine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Leflunomide.Approved, Investigational
LepirudinCastanospermine may increase the anticoagulant activities of Lepirudin.Approved
LeuprolideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololCastanospermine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCastanospermine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Castanospermine.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Castanospermine.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Castanospermine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Castanospermine.Approved
LomefloxacinCastanospermine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Castanospermine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Castanospermine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lumiracoxib.Approved, Investigational
LurasidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Castanospermine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Castanospermine.Approved
ME-609The risk or severity of adverse effects can be increased when Castanospermine is combined with ME-609.Investigational
MecaserminCastanospermine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Castanospermine.Approved, Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Castanospermine.Approved
Megestrol acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Castanospermine.Approved, Vet Approved
MesalazineCastanospermine may increase the nephrotoxic activities of Mesalazine.Approved
MestranolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Castanospermine is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Castanospermine.Approved
MethotrimeprazineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Castanospermine.Approved
MethylprednisoloneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetipranololCastanospermine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Castanospermine.Approved
MetoprololCastanospermine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideCastanospermine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneCastanospermine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Castanospermine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Castanospermine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Castanospermine.Approved
MoxifloxacinCastanospermine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Castanospermine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Castanospermine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nabumetone.Approved
NadololCastanospermine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCastanospermine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatCastanospermine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Castanospermine.Approved
Nalidixic AcidCastanospermine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Castanospermine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Castanospermine is combined with Natalizumab.Approved, Investigational
NateglinideCastanospermine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Castanospermine is combined with NCX 1022.Investigational
NeamineCastanospermine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NelfinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nelfinavir.Approved
NeomycinCastanospermine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nepafenac.Approved
NetilmicinCastanospermine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NiacinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
Niflumic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Niflumic Acid.Approved
NilotinibThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nitroaspirin.Investigational
NorethisteroneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Norethisterone.Approved
NorfloxacinCastanospermine may increase the neuroexcitatory activities of Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Norgestimate.Approved
OctreotideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinCastanospermine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Olanzapine.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Castanospermine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Castanospermine.Approved
OlsalazineCastanospermine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Castanospermine.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Castanospermine.Approved
OxprenololCastanospermine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oxyphenbutazone.Withdrawn
PaliperidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Paliperidone.Approved
PamidronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Parecoxib.Approved
ParomomycinCastanospermine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PasireotideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pasireotide.Approved
PazufloxacinCastanospermine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCastanospermine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCastanospermine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pentamidine.Approved
Pentosan PolysulfateCastanospermine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Castanospermine.Approved
PhenindioneCastanospermine may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonCastanospermine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Castanospermine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Castanospermine.Approved, Investigational
PindololCastanospermine may decrease the antihypertensive activities of Pindolol.Approved
PiperazineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pipotiazine.Approved
PirarubicinCastanospermine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideCastanospermine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Castanospermine.Approved, Investigational
PlicamycinCastanospermine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Castanospermine.Approved
PractololCastanospermine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Castanospermine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Castanospermine is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prednicarbate.Approved
PrednisoloneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Castanospermine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Propacetamol.Approved
PropranololCastanospermine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Castanospermine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Castanospermine.Experimental
Protein S humanCastanospermine may increase the anticoagulant activities of Protein S human.Approved
PrulifloxacinCastanospermine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Castanospermine is combined with PTC299.Investigational
PuromycinCastanospermine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuetiapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Castanospermine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Castanospermine.Approved
QuinineCastanospermine may increase the hypoglycemic activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Castanospermine.Approved
RepaglinideCastanospermine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Castanospermine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.Experimental, Investigational
ReviparinCastanospermine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinCastanospermine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Castanospermine is combined with CDX-110.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Risedronate.Approved, Investigational
RisperidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ritonavir.Approved, Investigational
RivaroxabanCastanospermine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Castanospermine.Approved
RosoxacinCastanospermine may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Castanospermine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Castanospermine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Castanospermine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Castanospermine.Experimental
SaquinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Saquinavir.Approved, Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Castanospermine is combined with Seratrodast.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Castanospermine.Approved
SirolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Sirolimus.Approved, Investigational
SisomicinCastanospermine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolCastanospermine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CCastanospermine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinCastanospermine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinCastanospermine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Castanospermine.Approved
SpironolactoneCastanospermine may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Castanospermine is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Castanospermine is combined with SRT501.Investigational
StreptomycinCastanospermine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinCastanospermine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineCastanospermine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleCastanospermine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineCastanospermine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleCastanospermine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Castanospermine.Approved
SulodexideCastanospermine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Castanospermine.Investigational
SunitinibCastanospermine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Castanospermine.Approved, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Castanospermine.Approved, Investigational
TacrolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Tacrolimus.Approved, Investigational
TacrolimusCastanospermine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Castanospermine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Castanospermine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Castanospermine.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Castanospermine.Approved, Investigational
TemafloxacinCastanospermine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Castanospermine.Experimental, Investigational
TemsirolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Temsirolimus.Approved
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Castanospermine.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Castanospermine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tiludronate.Approved, Vet Approved
TimololCastanospermine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tinoridine.Investigational
TipranavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tixocortol.Approved
TobramycinCastanospermine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibCastanospermine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideCastanospermine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideCastanospermine may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Castanospermine.Approved
TorasemideCastanospermine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Castanospermine.Approved
TranilastThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Castanospermine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Castanospermine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Castanospermine.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneCastanospermine may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Castanospermine.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TrovafloxacinCastanospermine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Castanospermine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinCastanospermine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Castanospermine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Castanospermine.Approved
VorinostatThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinCastanospermine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCastanospermine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Castanospermine.Approved, Investigational, Withdrawn
ZiprasidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zomepirac.Withdrawn
ZorubicinCastanospermine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility1110.0 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.6ChemAxon
logS0.77ALOGPS
pKa (Strongest Acidic)12.89ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area84.16 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity44.44 m3·mol-1ChemAxon
Polarizability18.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8918
Blood Brain Barrier-0.603
Caco-2 permeable-0.5805
P-glycoprotein substrateSubstrate0.6783
P-glycoprotein inhibitor INon-inhibitor0.8961
P-glycoprotein inhibitor IINon-inhibitor0.9806
Renal organic cation transporterNon-inhibitor0.6639
CYP450 2C9 substrateNon-substrate0.8783
CYP450 2D6 substrateNon-substrate0.6942
CYP450 3A4 substrateSubstrate0.5188
CYP450 1A2 substrateNon-inhibitor0.8141
CYP450 2C9 inhibitorNon-inhibitor0.9406
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.939
CYP450 3A4 inhibitorNon-inhibitor0.9974
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9942
Ames testNon AMES toxic0.7775
CarcinogenicityNon-carcinogens0.9757
BiodegradationNot ready biodegradable0.9638
Rat acute toxicity2.3961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6611
hERG inhibition (predictor II)Non-inhibitor0.9173
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-00o0-1932000000-28a09bc636766bb094b0View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as indolizidines. These are polycyclic compounds containing an indolizidine, which is a bicyclic heterocycle containing a saturated six-member ring fused to a saturated five-member ring, one of the bridging atoms being nitrogen.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassIndolizidines
Direct ParentIndolizidines
Alternative ParentsPiperidines / N-alkylpyrrolidines / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Polyols / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
SubstituentsIndolizidine / Piperidine / N-alkylpyrrolidine / Pyrrolidine / Tertiary aliphatic amine / Tertiary amine / Secondary alcohol / 1,2-aminoalcohol / Azacycle / Polyol
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptorsindolizidine alkaloid (CHEBI:27860 ) / Indolizidine alkaloids (C02256 )

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
unknown
General Function:
Transferase activity
Specific Function:
Major glucan 1,3-beta-glucosidase required for cell wall integrity. Beta-glucanases participate in the metabolism of beta-glucan, the main structural component of the cell wall. Can also function biosynthetically as a transglycosylase. Functions to deliver glucan from the cell to the extracellular matrix. Does not appear to impact cell wall glucan content of biofilm cells, nor is it necessary f...
Gene Name:
XOG1
Uniprot ID:
P29717
Uniprot Name:
Glucan 1,3-beta-glucosidase
Molecular Weight:
50037.635 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2017 16:36